SEARCH

SEARCH BY CITATION

References

  • 1
    Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51F58.
  • 2
    Miller KD, Jones E, Jack A et al. Visceral abdominal-fat accumulation associated with the use of indinavir. Lancet 1998; 51: 871875.DOI: 10.1016/s0140-6736(97)11518-5
  • 3
    Ward DJ, Delaney KM, Moorman AC et al. Description of lipodystrophy in HIV Outpatients Study (HOPS). International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. San Diego, CA, June 1999 [Abstract 10].
  • 4
    Miller JE, Emery S, French M, Baker D, Cooper DA. The Australian prevalence survey of lipodystrophy syndrome. VII Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January 2000 [Abstract 201].
  • 5
    Boubaker K, Sudre P, Flepp M et al. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study. VII Conference on Retroviruses and Opportunistic Infections San Francisco, CA, January 2000 [Abstract 57].
  • 6
    Martinez E, Mocroft A, Garcia-Viejo MA et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357: 592598.DOI: 10.1016/s0140-6736(00)04056-3
  • 7
    Purnell J, Zambon A, Knopp R et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14: 5157.DOI: 10.1006/bcon.1998.0668
  • 8
    Noor M, Lo J, Mulligan K et al. Metabolic effects of indinavir in healthy HIV-seronegative subjects. II International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada, September 2000 [Abstract O10:8].
  • 9
    Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycaemia, hyperlipidaemia and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160: 20502056.
  • 10
    Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV protease inhibitor-associated syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998; 351: 18811883.DOI: 10.1016/s0140-6736(98)03391-1
  • 11
    Martinez E, Garcia-Viejo MA, Blanco JL et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clin Infect Dis 2000; 31: 12661273.DOI: 10.1086/317426
  • 12
    Mitchell SW. Singular case of absence of adipose matter in the upper half of the body. Am J Med Sci 1885; 90: 105106.
  • 13
    Shalev A. Discovery of a lipodystrophy gene: one answer, one hundred questions. Eur J Endocrin 2000; 143: 565567.
  • 14
    Garg A. Lipodystrophies. Am J Med 2000; 108: 143152.DOI: 10.1016/s0002-9343(99)00414-3
  • 15
    Brinkman K, Smeitink JA, Romijn HA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-related lipodystrophy. Lancet 1999; 354: 11121115.DOI: 10.1016/s0140-6736(99)06102-4
  • 16
    Wentworth JM, Burris TP, Chatterjee VKK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPAR/RXR heterodimer. J Endocrin 2000; 164: R7R10.
  • 17
    Parker RA, Meyers DS, Andrews BA, Flint OP, Durham SK. Effects of nucleoside reverse transcriptase inhibitors and HIV protease inhibitors on adipogenesis and adipocyte metabolism. II International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada, September 2000 [Abstract O4:4].
  • 18
    Brinkman K, Ter Hofstede HJM, Burger DM, Smettink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 17351744.
  • 19
    Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25F32.DOI: 10.1097/00002030-200002180-00001
  • 20
    Shikuma C, Hu N, Milne C et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV infected individuals with peripheral lipoatrophy. AIDS in press.
  • 21
    Hutchison C, Alvarez-Reyes M, Vaughan OA. Lamins in disease: why do ubiquitously expressed nuclear envelope proteins give rise to tissue-specific disease phenotypes? J Cell Sci 2000; 114: 919.
  • 22
    Sullivan T, Escalante-Alcade D, Bhatt H et al. Loss of A-type lamin expression compromises nuclear envelope integrity leading to muscular dystrophy. J Cell Biol 1999; 147: 913919.
  • 23
    Behrens G, Lloyd D, Schmidt H et al. Lessons from lipodystrophy: LMNA, encoding lamin A/C, in HIV therapy-associated lipodystrophy. AIDS 2000; 14: 18541855.DOI: 10.1002/1097-0231(20001015)14:19[#60]1854::aid-rcm102[#62]3.0.co]2-m
  • 24
    Kahn SE, Prigeon RL, Schwartz RS et al. Obesity, body fat distribution, insulin sensitivity and islet-cell function as explanations for metabolic diversity. J Nutr 2001; 131: 354S360S.
  • 26
    Carr A. HIV protease inhibitor–related lipodystrophy syndrome. Clin Infect Dis 2000; 30 (Suppl 2): S135S142.DOI: 10.1086/313854
  • 25
    Berg J. Leptin is a potent anti-diabetic in mice with lipodystrophy and insulin resistance. Eur J Endocrinol 2000; 142: 114116.
  • 27
    Lenhard JM, Furfine ES, Jain RG et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000; 47: 121129.DOI: 10.1016/s0166-3542(00)00102-9
  • 28
    Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000; 20: 26252629.
  • 29
    Egger M. Metabolic complications of HAART. need for perspective. II International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Toronto, Canada, September 2000 [Abstract O23:15].
  • 30
    Hadigan C, Meigs J, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130139.DOI: 10.1086/317541
  • 31
    Smart EJ, Matveev S, Kincer J, Greenberg RN. Protease inhibitors up-regulate SR-BI and HDL-dependent cholesterol uptake in human macrophages: a mechanism that may enhance foam cell formation. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 662].
  • 32
    Mary-Krause M, Cotte L, Partisani M et al. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 657] .
  • 33
    Klein D, Hurley L, Sorel M, Sidney S. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients? Follow-up through June. VIII Conference on Retroviruses and Opportunistic Infections . Chicago, IL, February 2001 [Abstract 655].
  • 34
    Baldassarre D, Amato M, Bondioli A, Sirtori C, Tremoli E. Carotid artery intima-media thickness measured by ultrasonography in normal clinical practice correlates well with atherosclerosis risk factors. Stroke 2000; 31: 24262430.
  • 35
    Sosman JM, Klein MA, Bellehumeur JL, Aeschlimann SE, Stein JH. Endothelial dysfunction is associated with the use of human immunodeficiency virus type 1 protease inhibitors. VII Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, JanuaryFebruary 2000 [Abstract 29].
  • 36
    Cheminot N, Gariepy J, Chironi G et al. Diagnosis and determinants of subclinical arterial disease in HIV1-infected patients on HAART. VII Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, JanuaryFebruary 2000 [Abstract 31].
  • 37
    Depairon M, Chessex S, Sudre P et al. Premature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy. AIDS 2001; 15: 329334.DOI: 10.1002/(sici)1099-131x(199607)15:4[#60]329::aid-for610[#62]3.0.co]2-w
  • 38
    Mercie P, Tchamgoue S, Thiebaut R et al. Atherogen lipid profile in HIV-infected patients with lipodystrophy syndrome. Eur J Intern Med 2000; 11: 257263.DOI: 10.1016/s0953-6205(00)00103-5
  • 39
    Hadigan C, Corcoran C, Basgoz N et al. Metformin in the treatment of HIV lipodystrophy syndrome. A randomised controlled trial. JAMA 2000; 284: 472477.
  • 40
    Saint-Marc T & Touraine J-L. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 13: 10001002.DOI: 10.1002/(sici)1096-9136(199611)13:11[#60]1000::aid-dia169[#62]3.0.co]2-3
  • 41
    Miller J, Carr A, Brown D, Cooper DA. A randomised, double-blind study of gemfibrozil (GF) for the treatment of protease inhibitor-associated hypertriglyceridaemia. VIII Conference on Retroviruses and Opportunistic Infections.Chicago, IL, February 2001 [Abstract 540].
  • 42
    Arioglu E, Duncan-Morin J, Sebring N et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263274.
  • 43
    Walli RK, Michl GM, Bogner JR, Goebel FD. Effects of the PPAR-activator troglitazone on protease inhibitor associated peripheral insulin resistance. VI Conference on Retroviruses and Opportunistic Infections. Chicago, IL, January–February 1999 [Abstract 673].
  • 44
    Carr A, Hudson J, Chuah J et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomised controlled, open-label, multicentre study. AIDS, in press.
  • 45
    Tebas P, Yarasheski WG, Powderly E et al. A prospective open-label trial of a maintenance nevirapine (NVP)-containing regimen in patients with undetectable viral loads (VL) on protease inhibitor (PI) regimens for at least 6 months. VII Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, January–February 2000 [Abstract 45].
  • 46
    Thiebaut R, Daucourt V, Mercie P et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis 2000; 31: 14821487.DOI: 10.1086/317477
  • 47
    Martinez E, Romeu J, Garcia-Viejo MA et al. An open randomised study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1-infected patients with lipodystrophy. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 668].
  • 48
    Walli R, Huster K, Bogner JR et al. Switching from PI to ABC improves insulin sensitivity and fasting lipids – 12 month follow-up. VIII Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 2001 [Abstract 672].
  • 49
    Gavrilova O, Marcus-Samuels B, Graham D et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 2000; 105: 271278.
  • 50
    Galli M, Veglia F, Angarano G et al. Metabolic and morphological alterations under antiretroviral therapy: preliminary results of lipodystrophy Italian Multicentre Study (LIMS). AIDS 2000; 14 (Suppl 4): S54 [Abstract P133].
  • 51
    Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999; 13: 20992103.DOI: 10.1088/0022-3700/13/10/016
  • 52
    Baldini F, Di Giambenedetto S, Cingolani A et al. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS 2000; 14: 16601662.DOI: 10.1116/1.589207